Gapping up
In reaction to strong earnings/guidance:
- TKR +5.1%, HQY +1.9%
Other news:
- ARNA +35.2% (reports positive phase 2 results from the OASIS trial for etrasimod in patients with ulcerative colitis)
- CRME +12.1% (announces strategic transaction with Cipher Pharmaceuticals -- Cipher to acquire all outstanding shares of Cardiome, following a restructuring of Cardiome pursuant to a statutory plan of arrangement)
- FNJN +9.3% (received the $65 million payment due from Symantec; Halcyon Long Duration Recovery discloses 14.2% active stake)
- ELGX +8.2% (announces the first results from ENCORE, a pooled, global analysis of several prospective clinical trials and registries studying polymer endovascular aneurysm repair (Polymer EVAR) using Ovation Abdominal Stent Graft Systems)
- AMTX +6.5% (continuation of last week's move higher)
- KMPH +6.1% (announces that topline results from its ongoing pediatric and adolescent pharmacokinetic study suggest that following oral administration of its KP415 product candidate)
- BB +5.7% (BlackBerry and Microsoft partner to offer enterprises a solution that integrates BlackBerry's mobility/security with Microsoft's cloud/productivity products)
- APHB +3.2% (after announcing collaboration with the Western Sydney and the Westmead Institute for Medical Research based in Sydney, Australia)
- TRIL +2.6% (FDA Office of Orphan Products Development has granted an Orphan Drug Designation to TTI-621 for the treatment of cutaneous T-cell lymphoma)
Analyst comments:
- IIVI +2.2% (upgraded to Buy at B. Riley FBR)
- FCX +1.4% (initiated with a Buy at Goldman)
- CTRN +1.3% (upgraded to Buy from Neutral at MKM Partners)
- BHP +0.5% (upgraded to Neutral from Underperform at Exane BNP Paribas)